Clinical Trial Update: TGW211 for Click-Cleavable Imaging in HER2-Positive Cancers. [EARLY_Phase 1]

View source ↗

Summary

Clinical trial update indicating TGW211 as a click-cleavable imaging agent for HER2-positive cancers in an early-phase 1 study, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumor

Drugs mentioned

• TGW211

Snippet

Sponsor: Radboud University Medical Center | Conditions: HER2 Positive Solid Tumor | EARLY_Phase 1 | Status: RECRUITING